Literature DB >> 27045018

Lifting Up the HAT: Synthetic Lethal Screening Reveals a Novel Vulnerability at the CBP-p300 Axis.

Cigall Kadoch1.   

Abstract

Cancer genotype-specific synthetic lethal vulnerabilities represent promising therapeutic targets. In this issue of Cancer Discovery, Ogiwara and colleagues uncover a synthetic lethal relationship between two histone acetyl transferase paralogs, CBP and p300, highlighting that cancer cells deficient in CBP are uniquely sensitized to genetic and chemical inhibition of p300. ©2016 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27045018      PMCID： PMC5764754          DOI： 10.1158/2159-8290.CD-16-0163

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  11 in total

1.  Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers.

Authors:  Gregory R Hoffman; Rami Rahal; Frank Buxton; Kay Xiang; Gregory McAllister; Elizabeth Frias; Linda Bagdasarian; Janina Huber; Alicia Lindeman; Dongshu Chen; Rodrigo Romero; Nadire Ramadan; Tanushree Phadke; Kristy Haas; Mariela Jaskelioff; Boris G Wilson; Matthew J Meyer; Veronica Saenz-Vash; Huili Zhai; Vic E Myer; Jeffery A Porter; Nicholas Keen; Margaret E McLaughlin; Craig Mickanin; Charles W M Roberts; Frank Stegmeier; Zainab Jagani
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-11       Impact factor: 11.205

Review 2.  Exploiting epigenetic vulnerabilities for cancer therapeutics.

Authors:  Barbara Mair; Stefan Kubicek; Sebastian M B Nijman
Journal:  Trends Pharmacol Sci       Date:  2014-02-12       Impact factor: 14.819

3.  Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation.

Authors:  Boris G Wilson; Katherine C Helming; Xiaofeng Wang; Youngha Kim; Francisca Vazquez; Zainab Jagani; William C Hahn; Charles W M Roberts
Journal:  Mol Cell Biol       Date:  2014-01-13       Impact factor: 4.272

4.  A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.

Authors:  Takahiro Oike; Hideaki Ogiwara; Yuichi Tominaga; Kentaro Ito; Osamu Ando; Koji Tsuta; Tatsuji Mizukami; Yoko Shimada; Hisanori Isomura; Mayumi Komachi; Koh Furuta; Shun-Ichi Watanabe; Takashi Nakano; Jun Yokota; Takashi Kohno
Journal:  Cancer Res       Date:  2013-07-19       Impact factor: 12.701

5.  Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression.

Authors:  Hideaki Ogiwara; Mariko Sasaki; Takafumi Mitachi; Takahiro Oike; Saito Higuchi; Yuichi Tominaga; Takashi Kohno
Journal:  Cancer Discov       Date:  2015-11-24       Impact factor: 39.397

6.  Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP.

Authors:  F Petrij; R H Giles; H G Dauwerse; J J Saris; R C Hennekam; M Masuno; N Tommerup; G J van Ommen; R H Goodman; D J Peters
Journal:  Nature       Date:  1995-07-27       Impact factor: 49.962

7.  Inactivating mutations of acetyltransferase genes in B-cell lymphoma.

Authors:  Laura Pasqualucci; David Dominguez-Sola; Annalisa Chiarenza; Giulia Fabbri; Adina Grunn; Vladimir Trifonov; Lawryn H Kasper; Stephanie Lerach; Hongyan Tang; Jing Ma; Davide Rossi; Amy Chadburn; Vundavalli V Murty; Charles G Mullighan; Gianluca Gaidano; Raul Rabadan; Paul K Brindle; Riccardo Dalla-Favera
Journal:  Nature       Date:  2011-03-10       Impact factor: 49.962

8.  Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.

Authors:  Benjamin G Bitler; Katherine M Aird; Azat Garipov; Hua Li; Michael Amatangelo; Andrew V Kossenkov; David C Schultz; Qin Liu; Ie-Ming Shih; Jose R Conejo-Garcia; David W Speicher; Rugang Zhang
Journal:  Nat Med       Date:  2015-02-16       Impact factor: 53.440

9.  ARID1B is a specific vulnerability in ARID1A-mutant cancers.

Authors:  Katherine C Helming; Xiaofeng Wang; Boris G Wilson; Francisca Vazquez; Jeffrey R Haswell; Haley E Manchester; Youngha Kim; Gregory V Kryukov; Mahmoud Ghandi; Andrew J Aguirre; Zainab Jagani; Zhong Wang; Levi A Garraway; William C Hahn; Charles W M Roberts
Journal:  Nat Med       Date:  2014-02-23       Impact factor: 53.440

10.  Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.

Authors:  Anthony N Karnezis; Yemin Wang; Pilar Ramos; William Pd Hendricks; Esther Oliva; Emanuela D'Angelo; Jaime Prat; Marisa R Nucci; Torsten O Nielsen; Christine Chow; Samuel Leung; Friedrich Kommoss; Stefan Kommoss; Annacarolina Silva; Brigitte M Ronnett; Joseph T Rabban; David D Bowtell; Bernard E Weissman; Jeffrey M Trent; C Blake Gilks; David G Huntsman
Journal:  J Pathol       Date:  2015-12-21       Impact factor: 7.996
View more
  2 in total

Review 1.  Marked for death: targeting epigenetic changes in cancer.

Authors:  Sophia Xiao Pfister; Alan Ashworth
Journal:  Nat Rev Drug Discov       Date:  2017-03-10       Impact factor: 84.694

2.  Loci specific epigenetic drug sensitivity.

Authors:  Thanutra Zhang; Anna Pilko; Roy Wollman
Journal:  Nucleic Acids Res       Date:  2020-05-21       Impact factor: 16.971
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.